These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Orphan drugs and orphan tests in the USA. Thoene JG Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190 [No Abstract] [Full Text] [Related]
5. Rare opportunities appear on the horizon to treat rare diseases. Torres C Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483 [No Abstract] [Full Text] [Related]
6. "Creating hope" and other incentives for drug development for children. Connor E; Cure P Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312 [TBL] [Abstract][Full Text] [Related]
7. The Minor Use and Minor Species Animal Health Act: past, present, and future. Haley CJ Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456 [No Abstract] [Full Text] [Related]
8. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
9. Creation and development of the public service orphan drug Human Botulism Immune Globulin. Arnon SS Pediatrics; 2007 Apr; 119(4):785-9. PubMed ID: 17403850 [TBL] [Abstract][Full Text] [Related]
10. History of Orphan Drug Regulation-United States and Beyond. Haffner ME Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514 [TBL] [Abstract][Full Text] [Related]
11. The routes to orphan drug designation--our recent experience at the FDA. Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120 [No Abstract] [Full Text] [Related]
12. Incentives for drug development--the curious case of colchicine. Kesselheim AS; Solomon DH N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164 [No Abstract] [Full Text] [Related]
13. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Wellman-Labadie O; Zhou Y Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435 [TBL] [Abstract][Full Text] [Related]
14. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
15. How did uncommon disorders become 'rare diseases'? History of a boundary object. Huyard C Sociol Health Illn; 2009 May; 31(4):463-77. PubMed ID: 19397760 [TBL] [Abstract][Full Text] [Related]
16. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
17. Health care policy. Reforming off-label promotion to enhance orphan disease treatment. Liang BA; Mackey T Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234 [No Abstract] [Full Text] [Related]
18. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related]
19. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
20. Experimental use and the Orphan Drug Act: a biotechnology conundrum. Koivuniemi PJ Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930 [No Abstract] [Full Text] [Related] [Next] [New Search]